argenx N.V. has secured Zai Lab Ltd. as a partner in China for its closely watched pipeline-in-a-product efgartigimod, which has been touted as a future standard of care for the rare autoimmune disease myasthenia gravis (MG).
The Belgian-Dutch biotech has granted Zai Labs exclusive rights to develop and commercialize efgartigimod in mainland China, Hong Kong, Taiwan...